Artiva Biotherapeutics Inc. (ARTV) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Artiva Biotherapeutics Inc. (NASDAQ: ARTV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $4.19 (-0.95% 1D, market cap $206.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTV ranks #553 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARTV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M) and DTIL (Precision BioSciences Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per ARTV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817241), Artiva Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), -$83.9M in net income, and -$79.3M in free cash flow against $130.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 20.6 (OVERSOLD (<32))
20D Institutional Volume Accumulation (±12.5% realized swing band)
Capital intensity & 0% operating margin leave 16 pts on the table
While ARTV currently carries a cautious 39/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.11) and Max Pain ($4.40) forces dealer call-delta covering toward $15.26.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Artiva Biotherapeutics Inc. (ARTV) slipped -0.95% to $4.19, trading at 11% of its 52-week range ($2.96 – $14.53). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Major M&A deals this week include: Blue Matter buys Cognite, RadNet acquires ONRAD, Oak Hill Capital buys Wyyerd.
Oct. 27, 2026 U.S. top movers: BRAI led gainers at 73.58%, while DVLT led losers at -49.02%, ranked by percentage change.
Healthcare stocks were slightly lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.
Artiva Biotherapeutics Inc. (NASDAQ:ARTV) announced it will halt further clinical development of its lead cell therapy candidate, slash roughly 94% of its workforce, and evaluate strategic alternatives. The clinical-stag
A look at the biggest US stock movers on October 27, 2026, including the top percentage gainers and decliners with prices and context.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced on October 27, 2026, that it will discontinue development of its AlloNK (AB-101) cell therapy following a review of updated clinical results, longer-term patient outco
The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.
Today's gap stocks include gap-up leaders OPENZ, NEXR and MFIC, and gap-down movers DVLT, SPRC and ARTV, with gap sizes and session moves.
Artiva said it would reduce its workforce by about 94% and has hired Leerink Partners to explore strategic options, including a merger and asset sale.
Premarket movers ahead of the US open: BRAI, OPENZ, NEXR, XXII and AUROW among top gainers, while DVLT, SPRC, ARTV and ACTU lead declines.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARTV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARTV. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Artiva Biotherapeutics Inc. (ARTV) ranks #553 by composite RQD confidence (39/100, grade D-) and #572 by equity capitalization ($206.8M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with ARTV at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARTV
ACTIVE
Artiva Biotherapeutics Inc. | D- | 39/100 | — | — | -35.0% | -0.95% | $206.8M | Benchmark Subject |
| PALI Palisade Bio Inc. | D- | 43/100 | — | — | -35.0% | -2.52% | $207.4M | /pali-vs-artv → |
| DTIL Precision BioSciences Inc. | E | 24/100 | — | — | -35.0% | -5.11% | $205.4M | /dtil-vs-artv → |
| PLX Protalix BioTherapeutics Inc. | E | 28/100 | — | 48.8% | -13.0% | -0.77% | $210.3M | /plx-vs-artv → |
| CGEN Compugen Ltd. | B+ | 78/100 | 5.5x | 87.3% | 85.0% | -2.94% | $193.0M | /cgen-vs-artv → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artiva Biotherapeutics Inc. (ARTV) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $251.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$83.9M, operating cash flow of -$76.8M, and free cash flow of -$79.3M (-42.5% YoY). On the balance sheet, ARTV closed FY2025 with $130.9M in total assets against $0 in total debt (Altman Z-Score: 1.03, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$83.9M | -$76.8M | -$79.3M | $130.9M | — |
| FY2024 (FY) | 2024-12-31 | $251.0K | -$65.4M | -$55.0M | -$55.7M | $209.6M | — |
| FY2023 (FY) | 2023-12-31 | $32.9M | -$28.7M | -$47.4M | -$47.4M | — | — |
As of 2026-11-02, Artiva Biotherapeutics Inc. (NASDAQ: ARTV) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $4.19 (-0.95% 1D, market cap $206.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTV ranks #553 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARTV carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PALI (Palisade Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M) and DTIL (Precision BioSciences Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $205.4M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per ARTV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001817241), Artiva Biotherapeutics Inc. generated $0 in revenue (-100.0% YoY), -$83.9M in net income, and -$79.3M in free cash flow against $130.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ARTV last traded at $4.19 (-0.95% on volume of 1,966,179 shares), positioning the stock -48.34% below its 50-day simple moving average ($8.11) and -47.82% below its 200-day simple moving average ($8.03). Across its 52-week range of $2.96 to $14.53, ARTV sits at the 10.6% percentile with a 14-day RSI of 20.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.67 to $4.71).
Why ARTV Stock slipped -0.95% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).